Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/6/2024 | $5.00 → $2.00 | Neutral → Sell | Goldman |
| 1/31/2024 | Outperform → Market Perform | TD Cowen | |
| 1/31/2024 | $5.00 → $18.00 | Market Perform → Outperform | Leerink Partners |
| 10/30/2023 | $6.00 | Outperform → Market Perform | Leerink Partners |
| 10/12/2023 | $13.00 | Buy | Citigroup |
| 9/13/2023 | $5.00 | Buy → Neutral | Goldman |
| 9/12/2023 | Buy → Neutral | Guggenheim | |
| 7/28/2023 | $25.00 → $13.00 | Overweight → Equal-Weight | Morgan Stanley |
Goldman downgraded 2seventy bio from Neutral to Sell and set a new price target of $2.00 from $5.00 previously
TD Cowen downgraded 2seventy bio from Outperform to Market Perform
Leerink Partners upgraded 2seventy bio from Market Perform to Outperform and set a new price target of $18.00 from $5.00 previously
Acquisition by Bristol Myers Squibb on track to close in the second quarter of 2025: HSR waiting period expired on May 2, 2025; tender offer expected to expire on May 13, 2025 Abecma generated $59 million U.S. commercial revenue in the first quarter of 2025 Ended quarter with approximately $173 million in cash, cash equivalents, and marketable securities 2seventy bio, Inc. (NASDAQ:TSVT), today reported financial results and recent highlights for the first quarter ended March 31, 2025. "We started 2seventy with a singular focus on harnessing the power of cell therapy to deliver more time for people living with cancer," said Chip Baird, chief executive officer, 2seventy bio. "Over the pas
Entered into definitive merger agreement to be acquired by Bristol Myers Squibb at a price of $5.00 per share in an all-cash transaction; expected to close in the second quarter of 2025 Abecma generated $242 million U.S. sales in 2024 79% reduction in year-over-year net cash spend reflects continued streamlining of cost structure Ended 2024 with approximately $184 million in cash, cash equivalents, and marketable securities 2seventy bio, Inc. (NASDAQ:TSVT), today reported financial results and recent highlights for the fourth quarter and full year ended December 31, 2024. "2024 was a pivotal year for 2seventy as we made significant changes to our business to streamline cost structure a
$5.00 per share, all-cash transaction Expected to close in the second quarter of 2025, subject to customary closing conditions 2seventy bio, Inc. (NASDAQ:TSVT), today announced a definitive merger agreement under which Bristol Myers Squibb (NYSE:BMY) ("BMS") will acquire all of the outstanding shares of 2seventy bio at a price of $5.00 per share in an all-cash transaction for a total equity value of approximately $286 million, or $102 million net of estimated cash. The deal represents an 88% premium to the closing price of $2.66 on March 7, 2025. "A year ago, 2seventy decided to exclusively focus on unlocking the value of Abecma, with the goal of delivering more time for people living wi
4 - 2seventy bio, Inc. (0001860782) (Issuer)
4 - 2seventy bio, Inc. (0001860782) (Issuer)